In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Shares of Novo Nordisk surged over 13% in premarket trading Friday, driven by promising topline results from a early-stage trial of amycretin, a new weight-loss drug candidate. If gains hold, this ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday. View on euronews ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.

Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...

NOW OPEN: 200 Charter Memberships to Benzinga Trade Alerts On Friday, Novo Nordisk A/S NVO released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous ...

After Novo Nordisk (NVO) reported that subcutaneous amycretin demonstrated up to 22% absolute weight loss at 36-weeks in a Phase 1/2a trial, BofA thinks this “looks potentially best in class.” The ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...